PALANDRI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.126
AS - Asia 760
EU - Europa 606
SA - Sud America 85
AF - Africa 24
OC - Oceania 8
Totale 2.609
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.112
RU - Federazione Russa 302
CN - Cina 237
SG - Singapore 228
HK - Hong Kong 84
BR - Brasile 75
IT - Italia 72
KR - Corea 65
VN - Vietnam 65
IE - Irlanda 49
SE - Svezia 47
DE - Germania 39
FI - Finlandia 25
FR - Francia 23
IN - India 19
GB - Regno Unito 15
BD - Bangladesh 14
ID - Indonesia 10
CH - Svizzera 9
TR - Turchia 9
AU - Australia 8
CI - Costa d'Avorio 8
JO - Giordania 8
NL - Olanda 6
CA - Canada 5
JP - Giappone 5
UA - Ucraina 5
EC - Ecuador 4
MX - Messico 4
PL - Polonia 4
AR - Argentina 3
AT - Austria 3
IQ - Iraq 3
NG - Nigeria 3
BJ - Benin 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HN - Honduras 2
KE - Kenya 2
OM - Oman 2
RO - Romania 2
TH - Thailandia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CO - Colombia 1
DK - Danimarca 1
EG - Egitto 1
ES - Italia 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
JM - Giamaica 1
KZ - Kazakistan 1
LB - Libano 1
MA - Marocco 1
MM - Myanmar 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
Totale 2.609
Salva come PNG Salva come JPEG
Città #
Santa Clara 455
Singapore 183
Ashburn 152
Hefei 71
Hong Kong 70
Seoul 65
Chandler 63
San Jose 55
Dublin 49
Beijing 40
Los Angeles 24
Ho Chi Minh City 20
Altamura 18
Lawrence 18
Lauterbourg 17
Moscow 17
Fairfield 12
Munich 12
Buffalo 11
New York 11
Princeton 11
Boston 10
Council Bluffs 10
Hanoi 10
Helsinki 10
Seattle 10
Shanghai 10
Bern 9
Jacksonville 9
Jakarta 9
Abidjan 8
Cambridge 8
Kent 8
Lappeenranta 8
Milan 8
San Diego 8
Woodbridge 8
Boardman 7
Melbourne 7
Mumbai 7
The Dalles 7
Washington 7
Wilmington 7
Frankfurt am Main 6
London 6
Medford 6
Orem 6
São Paulo 6
Belo Horizonte 5
Houston 5
Paris 5
Tokyo 5
Andover 4
Chennai 4
Dallas 4
Izmir 4
Rome 4
Turku 4
Warsaw 4
Abuja 3
Bengaluru 3
Biên Hòa 3
Bremen 3
Brugherio 3
Chicago 3
Da Nang 3
Düsseldorf 3
Falkenstein 3
Florence 3
Haiphong 3
Vienna 3
Brooklyn 2
Charlotte 2
Cotonou 2
Curitiba 2
Detroit 2
Guangzhou 2
Guarulhos 2
Istanbul 2
Jinan 2
Johannesburg 2
Manchester 2
Nairobi 2
Norwalk 2
Osasco 2
Philadelphia 2
Phoenix 2
Pistoia 2
Salvador 2
Secaucus 2
Shenzhen 2
Taubaté 2
Thái Bình 2
Tianjin 2
Uberlândia 2
Addis Ababa 1
Ajman 1
Almaty 1
Amman 1
Ann Arbor 1
Totale 1.726
Salva come PNG Salva come JPEG
Nome #
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 162
A modified adenine chemically coupled to the allergen molecule of Dermatophagoides pteronyssinus redirects allergen-specific Th2 cells 155
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 155
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 152
A modified adenine chemically coupled to allergen molecule(s) induce Interferon-gamma production and down regulate IL-4 and IL-5 in Th2 specific T cells 149
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey 146
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 145
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study 141
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients 141
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis 138
Total serum IgE levels influence the in vitro detection of ss-lactams-specific IgE antibodies 137
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 132
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT 131
Incidence of blast phase in myelofibrosis according to anemia severity 130
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 130
Long-term follow-up of recovered MPN patients with COVID-19 127
Breakthrough infections in MPN-COVID vaccinated patients 118
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial 94
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options 94
null 15
Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators. Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 11
Health-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study. 6
Recommendations for best management of polycythemia vera in Italy: a Delphi consensus statement 6
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review 5
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design 5
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial 5
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis 4
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia 3
Totale 2.637
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.002
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.002
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 2 3
2021/202254 3 1 3 1 0 0 0 15 1 0 9 21
2022/2023251 18 56 15 17 17 37 26 17 29 5 3 11
2023/2024160 5 11 21 16 15 27 5 37 1 10 3 9
2024/20251.002 16 67 51 118 345 188 19 36 21 20 56 65
2025/20261.073 132 170 131 71 152 29 120 56 69 94 49 0
Totale 2.637